Chongqing Pharscin Pharmaceutical Co Ltd (002907) - Total Assets
Based on the latest financial reports, Chongqing Pharscin Pharmaceutical Co Ltd (002907) holds total assets worth CN¥2.00 Billion CNY (≈ $292.33 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Chongqing Pharscin Pharmaceutical Co Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Chongqing Pharscin Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see Chongqing Pharscin Pharmaceutical Co Ltd (002907) total market value for the company's overall valuation and market capitalisation.
Chongqing Pharscin Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Chongqing Pharscin Pharmaceutical Co Ltd's total assets of CN¥2.00 Billion consist of 53.8% current assets and 46.2% non-current assets. Review how much debt does Chongqing Pharscin Pharmaceutical Co Ltd carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 23.8% |
| Accounts Receivable | CN¥275.60 Million | 14.4% |
| Inventory | CN¥140.12 Million | 7.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥156.16 Million | 8.1% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Chongqing Pharscin Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Chongqing Pharscin Pharmaceutical Co Ltd for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chongqing Pharscin Pharmaceutical Co Ltd's current assets represent 53.8% of total assets in 2024, a decrease from 53.8% in 2013.
- Cash Position: Cash and equivalents constituted 23.8% of total assets in 2024, up from 7.4% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 7.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 14.4% of total assets.
Chongqing Pharscin Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Chongqing Pharscin Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Chongqing Pharscin Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.66 | 4.89 | 3.48 |
| Quick Ratio | 4.13 | 4.17 | 3.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥855.56 Million | CN¥806.45 Million | CN¥633.21 Million |
Chongqing Pharscin Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Chongqing Pharscin Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.62 |
| Latest Market Cap to Assets Ratio | 0.44 |
| Asset Growth Rate (YoY) | 3.6% |
| Total Assets | CN¥1.92 Billion |
| Market Capitalization | $846.95 Million USD |
Valuation Analysis
Below Book Valuation: The market values Chongqing Pharscin Pharmaceutical Co Ltd's assets below their book value (0.44x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Chongqing Pharscin Pharmaceutical Co Ltd's assets grew by 3.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Chongqing Pharscin Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual total assets of Chongqing Pharscin Pharmaceutical Co Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.92 Billion ≈ $280.60 Million |
+3.57% |
| 2023-12-31 | CN¥1.85 Billion ≈ $270.93 Million |
-0.81% |
| 2022-12-31 | CN¥1.87 Billion ≈ $273.15 Million |
+5.37% |
| 2021-12-31 | CN¥1.77 Billion ≈ $259.22 Million |
+2.91% |
| 2020-12-31 | CN¥1.72 Billion ≈ $251.90 Million |
+5.13% |
| 2019-12-31 | CN¥1.64 Billion ≈ $239.61 Million |
+49.73% |
| 2018-12-31 | CN¥1.09 Billion ≈ $160.03 Million |
+23.55% |
| 2017-12-31 | CN¥885.15 Million ≈ $129.52 Million |
+35.69% |
| 2016-12-31 | CN¥652.32 Million ≈ $95.46 Million |
+20.96% |
| 2015-12-31 | CN¥539.29 Million ≈ $78.92 Million |
+0.35% |
| 2014-12-31 | CN¥537.39 Million ≈ $78.64 Million |
+29.38% |
| 2013-12-31 | CN¥415.35 Million ≈ $60.78 Million |
-- |
About Chongqing Pharscin Pharmaceutical Co Ltd
Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs in China. The company offers tablets, powders, granules, soft capsules, powder injections, freeze-dried powders, injections, chemical raw materials, and small volume injections. It provides its products for the treatment of CNS, digestion, otolaryngology, oncology, cardiovascular, an… Read more